A 42-year-old with a past medical history of asthma was reviewed by you in the clinic. Asthma was diagnosed in childhood. In adulthood, he has had multiple admissions to the hospital with asthma exacerbations in the summer months and never required intubation and ventilation for these.
He reports a nocturnal cough up to three times per week. There are associated rhinorrhoea and dry eyes that have been present since the weather became a bit warmer. Currently, he is using a salbutamol inhaler every other day for wheeze and mild dyspnoea. He works in construction and finds that his symptoms are worse when he is outside. Three weeks ago he was admitted to the hospital with an exacerbation of his asthma, where he was treated with salbutamol nebulisers and a short course of prednisolone.
Other past medical history includes eczema, allergic rhinitis and idiopathic generalised epilepsy. He has not had a seizure for many years. Drug history reveals:
- 15. Salbutamol metered dose inhaler when required
- Salmeterol 50 micrograms/fluticasone propionate 500 micrograms – two puffs twice daily
- Levetiracetam 500mg twice daily
On examination, vital signs are all normal. Auscultation of the chest reveals some mild end expiratory wheeze in the upper posterior zones bilaterally. The jugular venous pressure is not elevated, heart sounds were dual with no murmurs and there was no pedal oedema.
Hb 13.9 g/dl
WBC 7 x 10^9/L (Neutr 4 x 10^9/L, Lymphos 1.5 x 10^9/L, Eosinophils 0.5 x 10^9/L)
Platelets 290,000
Sodium 140 mmol/L, Potassium 3.6 mmol/L, Urea 4 mmol/L, Creatinine 60 mcmol/L, C-reactive protein 2 mg/L
Aspergillus precipitins – Negative
IgE – 500 UI/ml (reference range 150 – 300 UI/ml)
Chest x-ray – Appears normal
Which of the following would be the most appropriate management for this patient?
The patient has poorly controlled allergic asthma with high IgE levels. Omalizumab is a subcutaneously administered monoclonal antibody that binds to circulating free IgE and prevents its interaction with the high-affinity IgE receptor on mast cells, aiming to prevent activation of mast cells by an antigen. Omalizumab has been shown to significantly reduce asthma exacerbations compared with placebo in adults (and adolescents) with severe persistent allergic asthma.